A viral-vector vaccine is a type of vaccine that uses an engineered virus as a delivery vehicle, or vector, to introduce genetic instructions into cells. These instructions cause cells to produce an antigen associated with a target pathogen or, in some experimental vaccines, a tumour. The immune system responds to that antigen and can develop immune memory. The vector is modified to make it suitable for vaccination; depending on its design, it may retain the ability to replicate or be unable to produce new infectious virus particles in the recipient.
How it works
A viral-vector vaccine contains a genetic sequence encoding the intended antigen, inserted into the vector’s genome. After administration, the vector enters susceptible cells and delivers this sequence. Cellular machinery then carries out gene expression, producing the antigen.
The resulting immune response involves several processes:
- Antibody production: immune cells recognize the antigen and can generate antibodies, including antibodies that block infection when directed against an appropriate target.
- Cell-mediated immunity: antigen fragments are presented to T cells, which can coordinate immune responses or recognize and destroy cells displaying the relevant antigen.
- Immune memory: some responding cells persist, enabling a faster response after subsequent exposure.
The vector itself also stimulates innate immune recognition, helping initiate the response. The strength and balance of immunity depend on the vector, antigen, dose, route of administration, and characteristics of the recipient.
Vector biology determines where genetic instructions are processed. Adenoviral vectors deliver DNA to the nucleus, where it is transcribed; integration into the recipient’s chromosomes is not required for their vaccine function. Other vector systems operate primarily in the cytoplasm. Viral-vector vaccination therefore should not be equated with permanent alteration of a person’s genome.
Main types
Non-replicating vectors
Replication-deficient vectors can enter cells and express the vaccine antigen but cannot complete a productive replication cycle in ordinary recipient cells. Essential viral genes may be deleted, with their functions supplied by specialized cells during manufacture.
Adenoviruses are widely used for this purpose. Human adenovirus types and adenoviruses originally isolated from other primates have both been developed as vaccine vectors. Several COVID-19 vaccines used non-replicating adenoviral platforms.
Modified vaccinia Ankara, or MVA, is another important vector platform. It is a highly attenuated poxvirus that does not productively replicate in most human cells and has been used in recombinant vaccine development.
Replicating vectors
Replication-competent vectors retain the ability to generate additional virus particles in the recipient. This can amplify antigen production and immune stimulation. Their safety characteristics depend on the particular virus and its attenuation or other modifications.
A prominent example is the recombinant vesicular stomatitis virus platform used in the Ebola vaccine Ervebo. In this vaccine, the gene encoding the vector’s surface glycoprotein is replaced by one encoding the Zaire ebolavirus glycoprotein.
The distinction between replicating and non-replicating vectors concerns the delivery virus, not whether the vaccine contains a replication-capable version of the pathogen against which protection is intended.
Development and established uses
Recombinant viral-vector vaccines emerged from advances in molecular virology and genetic engineering during the late twentieth century. Researchers learned to insert foreign antigen genes into viruses while modifying their replication and disease-causing properties.
An important clinical milestone was the authorization of Ervebo in the European Union and the United States in 2019 for prevention of disease caused by Zaire ebolavirus. Other Ebola vaccination approaches have combined an adenoviral vector with an MVA vector carrying Ebola antigens.
The COVID-19 pandemic brought adenoviral-vector vaccines into widespread use. Examples included Oxford–AstraZeneca’s ChAdOx1 vaccine, Janssen’s Ad26 vaccine, and other products developed using human adenovirus vectors. These vaccines encoded the spike protein of SARS-CoV-2, the virus responsible for COVID-19. Authorization, recommended uses, and availability have differed across jurisdictions and changed over time.
Viral vectors have also been investigated for vaccines against HIV, malaria, tuberculosis, and other infections. In cancer immunotherapy, experimental vector-based vaccines aim to stimulate responses against tumour-associated antigens. Use of a vector platform for one disease does not establish its effectiveness against another.
Advantages and technical limitations
Viral vectors deliver genetic material efficiently and can stimulate both antibody and T-cell responses. Once a platform is established, changing its antigen-encoding sequence can facilitate development of candidates against a different pathogen. Nevertheless, each candidate requires its own testing.
Important limitations include:
- Anti-vector immunity: previous exposure to a related virus, or immunity generated by an earlier vaccine dose, can reduce delivery or expression of the vaccine antigen.
- Booster constraints: repeated use of the same vector may be affected by anti-vector immunity. A heterologous prime–boost regimen uses different vectors or vaccine platforms for successive doses.
- Manufacturing complexity: production requires suitable cell systems, purification, and testing for identity, potency, consistency, and unwanted replication-capable contaminants where relevant.
- Storage requirements: stability and cold-chain needs are product-specific; they cannot be inferred from the platform name alone.
- Pathogen variation: changes in the target antigen can affect protection, as with other antigen-specific vaccines.
Protection against symptomatic disease, severe disease, infection, and onward transmission are distinct outcomes. Performance against one cannot automatically be assumed for the others.
Safety and evaluation
Safety assessment combines preclinical research, clinical trials, and post-authorization pharmacovigilance. Common reactions to several viral-vector vaccines include injection-site pain, headache, fatigue, muscle aches, and fever, although their frequency varies by product.
Rare but serious adverse reactions have been identified with particular vaccines. Thrombosis with thrombocytopenia syndrome, involving blood clots and low platelet counts, has been causally associated with certain adenoviral-vector COVID-19 vaccines. This finding does not establish the same risk for every adenoviral vaccine or every viral-vector platform.
Replication-capable vectors require assessment of potential vector-associated illness, shedding, and transmission. Replication-deficient vectors have different biological constraints, but that distinction alone does not establish overall safety. Product composition and the population studied remain important.
Relationship to other vaccine technologies
Unlike an inactivated vaccine, a viral-vector vaccine generally relies on cells to manufacture its principal target antigen. Unlike a protein subunit vaccine, it delivers genetic instructions rather than only the preformed antigen.
A live attenuated vaccine commonly uses a weakened version of the pathogen being targeted. A viral-vector vaccine usually uses a different virus as the carrier, although a replicating vector can itself be live and attenuated.
Viral-vector vaccines also share delivery techniques with gene therapy, but their intended function is different: vaccination principally seeks an immune response to an antigen, whereas gene therapy generally seeks to add, replace, or modify a biological function.